Retinopathy of prematurity (ROP) continues to be a potential major handicap for infants surviving neonatal intensive care. Its incidence and severity are greater in preterm infants ofless than 1500 g birth weight or of less than 31 weeks' gestation. Neonatal respiratory distress syndrome (RDS) is due to surfactant deficiency and occurs predominantly in preterm infants of less than 32 weeks' gestation. Pulmonary surfactant is a complex mixture of phospholipids and proteins produced by type II alveolar pneumocytes; deficiency leads to alveolar collapse, ventilation-perfusion abnormalities, and hypoxaemia so that supplemental oxygen must be given to maintain arterial oxygen tension (PaO2). Recent studies have shown that administration of exogenous natural surfactant to infants with RDS decreases neonatal mortality by 40%. ' The administration of exogenous natural surfactant is associated with an acute rise in PaO2. This can be closely monitored by pulse oximetry and the inspired oxygen concentration reduced rapidly to maintain an adequate PaO2 and prevent hyperoxaemia. Following surfactant therapy there is improved gas exchange for at least the first 72 hours of life and subsequently a reduction in neonatal deaths. 2 We were concerned that because of the increased survival rate of these extremely low birthweight babies associated with the large surge of PaO2 at the time of surfactant delivery that there may be an increased risk of ROP.
Surfactant therapy has only recently been established as routine management in RDS and few data exist about the subsequent eye complications. We decided to study the Discussion RDS is a common problem in the preterm neonate. Sixty five per cent of those babies of less than 1500 g develop RDS increasing to 80% of those less than 1000 g birth weight. 4 In this group hypoxia, hypercarbia, respiratory, and metabolic acidosis are commonplace. All these factors have been shown to be significantly associated with the development of acute ROP.567 Many individual risk factors have been implicated in the genesis of ROP suggesting that the common thread is neonatal illness with disturbed homeostasis upsetting the delicately balanced process of retinal development.7 Progression of ROP to advanced disease also seems to be largely determined by the severity of the early insult to the immature retina and is less influenced by prolonged or subsequent adverse effects.6 Surfactant therapy in the first 48 hours of life has been shown to have been a significant advance in improving the survival rate of these particularly sick neonates. 2 In treating the neonate with respiratory problems an arterial oxygen tension of 8-12 kPa is considered optimal. Surfactant therapy can cause an initial surge in oxygenation to levels of 20-30 kPa which is now closely monitored by pulse oximetry so that supplemental oxygen is reduced optimising tissue oxygenation and so avoiding the risks of hyperoxaemia.
The population of surfactant treated babies described in this study had severe RDS and were treated in a 'rescue' rather than a prophylactic trial. The comparison group did not have severe RDS and therefore were generally a less sick population. The results should be viewed with this disparity in mind so that the original hypothesis that there may be an increased risk of ROPin the sicker population requiring surfactant treatment was not sustained.
Estimates of the incidence of ROP in similar age and birthweight matched populations vary from 3-50%.89 Our rates of 25*9% in the surfactant group and 17-8% in the comparisons are therefore compatible. It is perhaps more relevant to study how many infants progress to threshold disease as this is the group in whom intervention with cryopexy is indicated.10 Only 1-7% of the surfactant group and 7X8% of comparisons reached threshold disease or greater and in the most at-risk population of less than 1000 g birth weight the incidence is 4% in the surfactant group and 16-3% in the comparisons. These differences are not significant but they confirm that despite being a sicker more at risk population babies receiving surfactant are not at increased risk of ROP.
Kalina has recently highlighted the concern that the increased survival of low birthweight infants and their prolonged oxygen dependence may increase their risk of ROP." It is our view that decreasing the severity of the early insult will decrease the risk of severe ROP. The value of surfactant therapy is not only in improving the survival of low birthweight infants but also decreasing the risk of severe ROP.
By improving oxygenation and stabilising infants' homeostasis in this early critical period subsequent prolonged oxygen dependence may not be as significant a factor in the genesis of ROP. Surfactant replacement therapy may have an important role in achieving this early stability. Further investigation is warranted to increase the numbers of infants treated with different types ofsurfactant and examined for ROP so that any potential beneficial effect can be confirmed.
